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Abstract
Background: The combination of sofosbuvir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as
well as the combination of SOF and RBV for the treatment of patients infected with hepatitis c virus (HCV) has
improved rates of sustained virological response (SVR) considerably in recent trials. However, there is only limited
data concerning the efficacy and safety in a “real-life” cohort.
Methods: We analyzed a cohort of 119 patients with chronic HCV infection treated at four investigational sites in
Germany. All patients received either a combination treatment of SOF, RBV and peg-IFN-alfa-2a or SOF and RBV.
Results: The rates of SVR at 12 weeks after end of treatment (SVR 12) were as follows: Among 76 patients with
genotype 1 infection the SVR 12 rate was 74 % (n = 56), among 14 patients with genotype 2 infection the SVR 12
rate was 79 % (n = 11), among 24 patients with genotype 3 infection the SVR 12 rate was 92 % (n = 22) and among
5 patients with genotype 4 infection the SVR 12 rate was 80 % (n = 4). Of all 26 patients with a relapse in our
cohort, 69 % (n = 18) of these patients presented with liver cirrhosis and 58 % (n = 15) were treatment experienced.
Notably, the level of HCV-RNA after 4 weeks of treatment was a significant predictor of treatment response in
genotype 1 patients. Patients with HCV-RNA levels ≥ 12 IU ml-1 after 4 weeks of treatment achieved SVR 12 only in
30 % (n = 17/56, p < 0.0001) of cases and treatment response was even lower with SVR 12 of 25 % (n = 5/20,
p = 0.0016) in the subgroup of patients with cirrhosis.
Conclusion: We observed a high rate of SVR 12 with SOF-based treatment regimes, however probably due to the
high number of patients with liver cirrhosis and prior treatment experience, treatment response rates were lower
than in previously published trials. In genotype 1 patients the analysis of early virological response may predict
treatment response in SOF-based combination therapies.
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Background
Chronic hepatitis C virus (HCV) infection affects an es-
timated 170 million people worldwide with a prevalence
of approximately 0.2–2 % in the United States and
Europe [1, 2]. As HCV patients are at risk for developing
end-stage liver disease with a variety of complications in-
cluding hepatocellular carcinoma and decompensated
liver cirrhosis with the need for liver transplantation,
chronic HCV infection is associated with an elevated
risk for liver-related mortality [3–5].
The next generation direct acting antiviral (DAA)
sofosbuvir (SOF), which has been recently approved by
national health authorities, represents the next milestone
in the development of new therapeutic options and
opens up potent treatment regimes for chronic HCV pa-
tients. SOF is an oral nucleotide analogue inhibitor of
the HCV-specific NS5B polymerase with high antiviral
efficacy and a favorable safety profile [6–8]. The efficacy
of SOF-based treatment regimes has been demonstrated
in different phase II and phase III trials [9, 10].
However, due to preselected patient populations and
underrepresentation of difficult-to-treat patients, such as
treatment experienced cirrhotics, these data may differ
in a real-life setting and the validation of these results in
a diverse patient population with less favorable condi-
tions towards an SVR regarding concomitant diseases or
constitutional factors may yield additional aspects and
knowledge valuable for the future management of af-
fected patients [11, 12].
Thus, we aimed to investigate the efficacy and safety
of the SOF-based treatment regimes SOF, RBV and peg-
IFN-alfa-2a or SOF and RBV alone in our “real-life” co-
hort from four tertiary referral centres in Germany.
Patients and methods
Patient population and study design
We analyzed clinical and laboratory data of all consecu-
tive patients aged 18 years or older with treatment initi-
ation for chronic HCV genotype 1, 2, 3 or 4 infection
between January and June 2014 in a retrospective, longi-
tudinal study at four investigational sites in Germany.
One patient was non-adherent to the antiviral treatment
plan and showed no SVR. This patient was included in
the intention-to-treat (ITT) analysis.
Patients were treated with a combination treatment of
SOF, RBV and peg-IFN-alfa-2a or SOF and RBV for either
12 or 24 weeks, depending on genotype, pretreatment his-
tory, presence of liver cirrhosis or contraindications ac-
cording to the approved treatment recommendations [13].
SOF was administered at 400 mg once daily and RBV dose
was based on body weight (1000 mg per day for <75 kg
and 1200 mg per day for ≥75 kg in a divided dose) in all
patients. Peg-IFN-alfa-2a was applied at a dosing of
180 μg once weekly to patients with genotype 1, 3 or 4
according to the individual treatment protocol. Serum
HCV-RNA and standard laboratory tests were regularly
assessed at baseline, at weeks 4, 12 and 24 of treatment
and at additional time points, if deemed necessary, as well
as at 12 weeks of follow-up. The lower limit of quantifica-
tion (LLOQ) was 12 IU/ml (Abbott RealTime (ART) HCV
assay (Abbott Molecular, Des Plaines, IL, USA). Liver cir-
rhosis was confirmed by liver histology or by evaluation of
data sets from non-invasive tests, comprising fibroscan
measurement, ultrasound examination, imaging by com-
puted tomography or magnetic resonance, presence of
esophageal varices and laboratory values. No patient with
decompensated liver cirrhosis was included in the analysis.
The institutional Ethics Committee (Ethikkommission der
Medizinischen Fakultät Heidelberg) approved the protocol
and the study was conducted in accordance with the
Guidelines for Good Clinical Practice and the Declaration
of Helsinki.
Statistical analysis
Continuous data are expressed by mean values and
standard deviation. Categorical variables are expressed
as absolute and relative numbers. Continuous data over
time was analyzed with one-sample t-test and categorical
data with chi-square test. A p value <0.05 was consid-
ered statistically significant. Statistical analysis was per-
formed using GraphPad Prism software (version 6.0,
GraphPad Software, Inc., La Jolla, CA, USA).
Results
Characterization of the study population
We enrolled 119 patients with chronic HCV infection at
four investigational sites in Germany. HCV genotype 1
was present in 64 % (n = 76) of patients, followed by
genotype 3 in 20 % (n = 24), genotype 2 in 12 % (n = 14)
and genotype 4 in 4 % (n = 5) of patients. The study
population consisted of a large proportion of patients
with liver cirrhosis 46 % (n = 55). Of all patients, 50 %
(n = 60) were treatment experienced and 23 % (n = 27)
had received a protease inhibitor in a previous therapy.
The patient population comprised patients co-infected
with human immunodeficiency virus (HIV) (n = 9) as
well as patients after liver transplantation (n = 14). The
distribution of patients after liver transplantation among
genotypes was 7 patients with genotype 1 and 7 patients
with genotype 3. Baseline characteristics of the study co-
hort are shown in Table 1. A combination treatment of
SOF, RBV and peg-IFN-alfa-2a was administered to 68 %
(n = 81) of patients and 32 % (n = 38) of patients were
treated with SOF and RBV for 12 to 24 weeks. In detail,
patients with genotype 1 received either a therapy re-
gime of SOF + peg-IFN-alfa-2a + RBV over 12 weeks
(43 % (n = 51)) or 24 weeks (10 % (n = 12)) or a therapy
regime of SOF + RBV over 24 weeks (11 % (n = 13)).
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Patients with genotype 2 were exclusively treated with a
12-week regimen of SOF and RBV (12 % (n = 14)). A
therapy regime of SOF + peg-IFN-alfa-2a + RBV over
12 weeks was applied in 12 % (n = 14) and of SOF + RBV
over 24 weeks in 8 % (n = 10) of patients with genotype
3. In patients with genotype 4 the therapy regimes and
treatment duration was SOF + peg-IFN-alfa-2a + RBV
over 12 weeks in 3 % (n = 4) and SOF + RBV over
24 weeks in 1 % (n = 1) of cases (Table 2).
Efficacy of sofosbuvir-based therapies
The SVR 12 rates according to the HCV genotype were
as follows: Among 76 patients with genotype 1 infection
the SVR 12 rate was 74 % (n = 56), 14 patients with
genotype 2 infection had a SVR 12 rate of 79 % (n = 11),
among 24 patients with genotype 3 infection the SVR 12
rate was 92 % (n = 22) and 5 patients with genotype 4 in-
fection achieved a SVR 12 rate of 80 % (n = 4). Overall, 26
patients experienced a relapse in our cohort, 69 % (n = 18)
of these patients presented with liver cirrhosis and 58 %
(n = 15) were treatment experienced. The patient group
with cirrhosis and previous treatment experience had the
lowest SVR 12 rates in all four genotypes. Out of all 26 pa-
tients with a relapse in our cohort, 50 % (n = 13) presented
with both negative predictors (Fig. 1).
In a subgroup of patients with genotype 1 HCV infec-
tion treated with SOF plus RBV and peg-IFN-alfa-2a for
12 weeks SVR 12 rates were 80 % (n = 41/51) and in
those treated for 24 weeks SVR 12 rates were 75 % (n =
9/12). The results in both groups were not statistically
different (p = 0.6779). However, it has to be considered
that 11 out of 12 patients treated over a 24-week period
with this regimen had cirrhosis and were treatment-
experienced.
Further analysis indicated that besides the presence of
cirrhosis, the level of HCV-RNA by week 4 of treatment
was a significant predictor of treatment response in our
genotype 1 population (Table 3). Patients with HCV-
RNA levels ≥ 12 IU ml-1 after 4 weeks of treatment
achieved SVR 12 only in 30 % of cases and treatment re-
sponse was even lower with SVR 12 of 25 % in the sub-
group of genotype 1 patients with cirrhosis (Fig. 2).
Interestingly, HCV-RNA levels ≥ 12 IU ml-1 after 4 weeks
of treatment was only associated with treatment failure in
patients receiving an IFN-containing regime but not in pa-
tients on SOF + RBV (Fig. 3). In patients with HCV geno-
type 1 infection, there was a significant decline in total
bilirubin levels when comparing the time points of treat-
ment initiation and of SVR 12 (Table 4).
Side effects of sofosbuvir-based therapies
In the treatment regimes consisting of SOF plus RBV and
peg-IFN-alfa-2a as well as consisting of SOF plus RBV
alone, the most common adverse events were fatigue and
myalgia. No severe adverse events were reported. There
was a significant difference in the reported side effect of
hair loss in the two groups. With respect to hematologic
abnormalities, anemia was most frequently observed, an
event that is consistent with the well-known side effects of
peg-IFN-alfa-2a and RBV. The rates of anemia, reduced
white cell count and platelet count differed significantly
between the two treatment groups. The SOF plus RBV
therapy regime was generally well tolerated with fewer ob-
served side effects as compared to the treatment with SOF
plus RBV and peg-IFN-alfa-2a (Table 5).
Discussion
The approval of SOF, the novel nucleotide analogue
NS5B polymerase inhibitor, represents a breakthrough in
the treatment of chronic HCV and has become the
Table 1 Baseline characteristics of the study population
Demographics
Mean age (years) 50 ± 12 (20–77)
Male sex 74 % (88)
HCV genotype
1a 20 % (23)
1b 44 % (53)
2 12 % (14)
3 20 % (24)
4 4 % (5)
Mean HCV-RNA (10E6 IU ml-1) 3.23 ± 6.61 (0.02–34.50)
Cirrhosis 46 % (55)
Treatment history
Treatment naive 50 % (59)
Treatment experienced 50 % (60)
Protease inhibitor experienced 23 % (27)
Clinical chemistry
Platelets (10E3 μl-1) 155 ± 74 (13–396)
Total bilirubin (mg dl-1) 1.0 ± 0.8 (0.2–4.7)
INR 1.09 ± 0.25 (0.84–2.65)
Creatinine (mg dl-1) 0.78 ± 0.21 (0.43–1.85)
Data are expressed as percent (number) or means ± SD (range)
Table 2 Therapy regime and treatment duration
GT 1 GT 2 GT 3 GT 4
SOF + PEG + RBV
12 weeks 43 % (51) 0 12 % (14) 3 % (4)
24 weeks 10 % (12) 0 0 0
SOF + RBV
12 weeks 0 12 % (14) 0 0
24 weeks 11 % (13) 0 8 % (10) 1 % (1)
Data are expressed as percent (number)
GT genotype, SOF sofosbuvir, PEG pegylated-interferon, RBV ribavirin
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backbone of current therapy regimes. SOF-based therapies
are the novel standard of care with high antiviral activity,
broad genotypic coverage and a high barrier to resistance
[6–8, 14, 15]. During therapy with SOF, no virological
breakthrough has been reported so far [14, 16].
However, many difficult-to-treat patient populations
hitherto have been understudied. Thus, we included a
high number of patients with cirrhosis in our study,
since HCV treatment represents a high priority particu-
larly in this patient group. As HCV recurrence after liver
transplantation is universal and bears a high risk of
premature graft failure, we also analyzed patients after
liver transplantation in our study. Previously, in the
abovementioned patient groups, IFN-based HCV therap-
ies were limited because of toxicity and poor efficacy [4].
Additionally, many patients in our study were treatment
experienced and several of those had received a protease
inhibitor in a previous therapy. The study population
further comprised patients co-infected with human im-
munodeficiency virus (HIV). Recent data has shown that
the outcome of DAA-based therapies in HCV/HIV co-
infected patients is comparable to the HCV cure rates in
Fig. 1 Efficacy of treatment of the study patients. Sustained virological response rates after 12 weeks after the end of treatment (SVR 12) are
shown for patients with HCV genotype 1, 2, 3 or 4 (a–d). Patients were sub-classified for previous treatment experience or presence of cirrhosis.
n = total number of patients
Table 3 Predictors of response for patients with HCV genotype 1 infection
SVR 12 Relapse p value
total: 74 % (56) total: 26 % (20)
Age <65 years 95 % (53) 85 % (17) 0.1698
Age ≥65 years 5 % (3) 15 % (3)
Female 34 % (19) 20 % (4) 0.2445
Male 66 % (37) 80 % (16)
Non-cirrhotic 64 % (36) 35 % (7) 0.0233
Cirrhotic 36 % (20) 65 % (13)
Treatment naive 52 % (29) 45 % (9) 0.6024
Treatment experienced 48 % (27) 55 % (11)
HCV-RNA <6 (10E6 IU ml-1) at baseline 79 % (44) 85 % (17) 0.5352
HCV-RNA ≥6 (10E6 IU ml-1) at baseline 21 % (12) 15 % (3)
HCV-RNA <12 (IU ml-1) after 4 weeks of treatment 70 % (39) 35 % (7) 0.0065
HCV-RNA ≥12 (IU ml-1) after 4 weeks of treatment 30 % (17) 65 % (13)
Platelets <100 (10E3 μl-1) at baseline 18 % (10) 30 % (6) 0.2529
Platelets ≥100 (10E3 μl-1) at baseline 82 % (46) 70 % (14)
Data are expressed as percent (number)
SVR 12 sustained virological response at 12 weeks after end of treatment
Boldface data statistically significant
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HCV mono-infected patients and indication and drug
choice should follow the general guidelines for HCV
mono-infected subjects [17]. Therefore, HCV/HIV co-
infected individuals are no longer regarded as a special
patient population by major guidelines [13]. Instead,
with current DAA-based therapies, genotype 3 infected
patients or special populations, including patients with
renal insufficiency or decompensated cirrhosis, have
shifted into the focus as difficult-to-treat populations.
Considering overall SVR 12 rates, patients with HCV
genotype 1 infection, which historically have been diffi-
cult to treat, still seem to be the population hardest to
cure, as also reflected by our study results [10, 14, 17].
In the NEUTRINO trial, a phase 3 study in previously
untreated patients with HCV genotype 1, a 12-week regi-
men of SOF plus RBV and peg-IFN-alfa-2a was adminis-
tered. Total SVR 12 rates were 90 % and SVR 12 rates
for patients with cirrhosis were 80 %. [14]. In a further
small study involving treatment-naive patients with
HCV genotype 1 infection and a high prevalence of ad-
vanced fibrosis and cirrhosis, a 24-week regimen of SOF
and RBV resulted in SVR rates of 68 % [8, 18]. In our
study population total SVR 12 rates were 74 % and SVR
12 rates for patients with cirrhosis were 57 %. While
overall virological response rates are encouraging, the
relative high relapse rate in genotype 1 patients may
suggest that dual DAA combinations should be favored
at least for patients with negative predictors for a suc-
cessful treatment outcome.
Surprisingly, total SVR 12 rates for patients with geno-
type 2 were lower than expected. In contrast to the re-
sults in our study population, the combination of SOF
plus RBV has yielded very favorable results in previous
studies [9, 14, 19, 20]. In the FISSION trial, a phase 3
study involving previously untreated patients with HCV
genotype 2 infection, a 12-week regimen of SOF and
RBV showed total SVR 12 rates of 95 % and SVR 12
rates of 83 % for patients with cirrhosis [14]. In compari-
son, total SVR 12 rates for patients with genotype 2 in
our collective was 79 % and was only 50 % regarding pa-
tients with cirrhosis.
Fig. 2 HCV-RNA level after 4 weeks of treatment as a predictor of
response. Association of sustained virological response rates after
12 weeks after the end of treatment (SVR 12) of all patients with
HCV genotype 1 infection with a level of HCV-RNA either < 12 IU –ml
or≥ 12 IU –ml after 4 weeks of treatment (a) and solely for patients
with HCV genotype 1 and cirrhosis (b). n = number of patients.
*p < 0.0001, **p = 0.0016
Fig. 3 Association of RVR for SVR 12 with regard to either IFN-
containing or IFN-free treatment regime. Association of sustained
virological response rates after 12 weeks after the end of treatment (SVR
12) with RVR (level of HCV-RNA either < 12 IU –ml) for patients with HCV
genotype 1 infection receiving either SOF + PEG + RBV (a) or SOF + RBV
(b). n = number of patients. **p< 0.0001. n.s. = non significant
Table 4 Change from baseline to SVR 12 in patients with HCV
genotype 1 infection
Baseline SVR 12 p value
Platelets (10E3 μl-1) 171 ± 81 173 ± 76 0.8913
Total bilirubin (mg dl-1) 1.2 ± 1.0 0.7 ± 0.4 0.0052
INR 1.03 ± 0.12 1.06 ± 0.21 0.4964
Creatinine (mg dl-1) 0.77 ± 0.18 0.80 ± 0.17 0.5529
Data are expressed as means ± SD
SVR 12 sustained virological response at 12 weeks after end of treatment
Boldface data statistically significant
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Furthermore, in genotype 3 infected HCV patients,
which have previously emerged as a particularly difficult
to treat patient group, total SVR 12 rates in our study
turned out to be higher than projected. The VALENCE
trial yielded for previously treated and untreated patients
with HCV genotype 3 infection total SVR 12 rates of 77–
93 % after a 24-week regime of SOF and RBV, while the
subgroup of previously treated cirrhotic patients displayed
only SVR 12 rates of 61 % [9, 14, 16, 19]. With the
addition of peg-IFN-alfa-2a to 12 weeks of SOF plus RBV
in the LONESTAR-2 trial SVR 12 rates of 83 % were
achieved in this unfavorable subgroup of previously
treated cirrhotics [20]. It can be speculated that these posi-
tive results may reflect a selection of patients with early
stage cirrhosis with only minimally lowered thrombocyte
counts, which were therefore regarded to be eligible to
receive IFN. The patients in our collective showed total
SVR 12 rates of 92 % and even treatment-experienced
cirrhotics showed a SVR 12 rate of 87 % despite an
interferon-free treatment regime in most of the cases.
Eventually these data suggest that besides SOF plus RBV
for 24 weeks, a SOF plus RBV and IFN treatment for
12 weeks should still be considered for IFN-eligible geno-
type 3 patients.
The NEUTRINO trial, a study of SOF plus RBV and
peg-IFN-alfa-2a in previously untreated patients with
HCV genotype 4, presented total SVR 12 rates of 97 %
and for patients with cirrhosis of 50 % [14]. Correspond-
ing rates in our study population were 80 and 50 %.
However, it has to be noted that a comparison of the
data of the aforementioned trials with the results of our
study population is limited due to differences regarding
the inclusion of treatment experienced patients and the
treatment of patients with either one of two available
treatment options and variable treatment duration.
Interestingly, besides the presence of cirrhosis, we ob-
served that a level of HCV-RNA ≥ 12 IU ml-1 by week 4 of
treatment was a predictor for treatment failure in genotype
1 patients, despite the fact that early virological response
appeared to be of limited value as a prognostic marker in
previously published DAA-based studies [14, 20]. Regard-
ing the subgroup of cirrhotics, SVR 12 rates were only
25 % when HCV-RNA levels were ≥ 12 IU ml-1 after
4 weeks of treatment. Notably, the predictive value of early
virological response was only evident in genotype 1 patients
receiving an IFN-containing regime, but not in patients on
SOF + RBV. Taken into account that SOF + peg-IFN-alfa-
2a + RBV may still remain the standard of care in many re-
gions of the world, because of the high costs of IFN-free
treatment regimes, analysis of early virological response
may be helpful to establish response-guided therapy re-
gimes in the future. However, the sensitivity of HCV RNA
Table 5 Adverse events and hematologic abnormalities
SOF + PEG + RBV SOF + RBV p value
total: 68 % (81) total: 32 % (38)
Adverse events
Headache 5 % (4) 5 % (2) 0.9515
Fatigue 18 % (14) 16 % (6) 0.8170
Myalgia 15 % (12) 11 % (4) 0.5072
Hashimoto’s thyroiditis 5 % (4) 0 0.1608
Decreased appetite 3 % (2) 0 0.3256
Rash 5 % (4) 0 0.1608
Thrush 1 % (1) 0 0.4888
Hair loss 10 % (8) 0 0.0435
Aggressiveness 6 % (5) 0 0.1153
Pruritus 5 % (4) 0 0.1608
Insomnia 3 % (2) 3 % (1) 0.9662
Depression 3 % (2) 0 0.3256
Acute psychosis 1 % (1) 0 0.4888
Hematologic abnormalities
Anemia (<10 g dl-1) 75 % (60) 37 % (14) <0.0001
Leukocytopenia (<3 10E3 μl-1) 75 % (60) 16 % (6) <0.0001
Thrombocytopenia (<100 10E3 μl-1) 60 % (48) 5 % (2) <0.0001
Data are expressed as percent (number)
SOF sofosbuvir, PEG pegylated-interferon, RBV ribavirin
Boldface data statistically significant
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quantification can differ between different tests. Patients
who may have tested HCV RNA negative during antiviral
therapy by older assays with a LLOQ of ≥ 50 IU/ml may
test HCV RNA positive by highly sensitive HCV RNA as-
says. In our study the highly sensitive Abbott RealTime
(ART) HCV assay (Abbott Molecular, Des Plaines, IL,
USA) with the LLOQ of 12 IU/ml was used. Therefore, it
might be reasonably assumed that different assays may
have an influence on the predictive value of the early treat-
ment response [21, 22].
Change in clinical chemistry from baseline to SVR 12
in patients with genotype 1 HCV infection showed a sta-
tistically significant decline in total bilirubin. It might be
speculated that the observed change in total bilirubin
under successful HCV therapy in genotype 1 patients
could be translated into an improvement of the MELD
score of patients with advanced stages of liver cirrhosis
and therefore treatment may lead to a delay or perman-
ent prevention of liver transplantation.
As a limitation of the study, there is no data on the
interleukin 28B haplotype of the patients in our cohort
available. An association of viral clearance with this
polymorphism was shown for antiviral treatment with
peg-IFN-alfa and RBV, but not for SOF so far [23, 24].
In our patient cohort no data is available on baseline and
post-treatment resistance–associated variants (RAVs) repre-
senting a further limitation of our study. However, SOF ex-
hibits a high barrier to resistance and among patients who
did not achieve SVR in recent trials, including the FISSION,
POSITRON and VALENCE trials, SOF resistance–
associated variants (RAVs) were not detected [9, 14, 19].
On the other hand, the Q80K variant conferring resistance
to the NS3 protease inhibitor simeprevir has been observed
in 9-48 % of untreated HCV genotype 1a-infected patients,
leading to reduced SVR rates [25]. Although patients with
baseline RAVs still exhibit high SVR rates, screening for
variants conferring resistance may help to reduce treatment
failures with respect to cost intensive treatment regimes.
Consistent with the safety profile of IFN, adverse
events and laboratory abnormalities were more common
in the SOF, RBV and peg-IFN-alfa-2a group. As seen in
our study, adverse event profiles improve substantially in
the absence of IFN. In view of the inconvenience and
high rate of significant side effects of IFN, all-oral, IFN-
free DAA therapies will become the first choice for
treatment of patients with chronic HCV.
However, even though great strides have been made
since the approval of the first DAAs in 2011, future re-
search needs to address the current limitations in the anti-
viral efficacy of available therapies in the increasing
number of patients with advanced liver disease and previ-
ous DAA treatment failure. With a growing number of pa-
tients who have failed under DAA-based therapy, there is
still an emerging demand for further novel antiviral agents.
Conclusion
SOF-based therapy regimes are safe and lead to high rates
of SVR 12. However, probably due to a large proportion of
patients in our cohort with unfavorable conditions such as
liver cirrhosis or pre-treatment failure or even the com-
bination of both, the SVR rates of previous clinical trials
were not attained in our patient cohort.
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